• Definium Therapeutics granted six newly hired non-executive employees options to purchase 93,320 common shares under its 2026 Inducement Plan.
• The options carry an effective grant date of October 26, 2026, following Compensation Committee approval on October 23, 2026.
• Vesting spans four years: 25% on the first grant anniversary, with the remaining 75% in substantially equal monthly installments over three years.
• All vesting is subject to each employee’s continued employment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261026727263) on October 26, 2026, and is solely responsible for the information contained therein.